Researchers concluded that a subgroup of [Alzheimers] patients aged 65 or younger may benefit from treatment with [ALCAR] whereas older individuals might do more poorly. 13 A follow up study reanalyzed the results and came to similar conclusions, suggesting that ALCAR slows the progression of Alzheimers disease in younger subjects. 14 In another follow-up study that compared ALCARs effect on those with early-onset (age 45-65) and regular Alzheimers, researchers reached a different conclusion, reporting that there were no significant differences between the treatment groups. 15 ALCAR 1,500 mg seems to help with depression in the elderly In this study, 28 elderly patients aged 70-80 who had been diagnosed with depression were given either 1,500 mg Acetyl-L-Carnitine or placebo daily, and were then evaluated with three cognitive tests and by clinical observation
Both peptides have been studied individually and in mix, providing large safety data for researchers
For example, during structural LTP (sLTP) induced by the glutamate uncaging at single spines of cultured hippocampal neurons, RhoA and Cdc42 activity was transiently increased and then decayed to a slight but stable elevation, coinciding with spine volume enlargement during sLTP (Murakoshi et al., 2011)
One was clinical
The phases are therefore about climbing , not cycling: Initiation (weeks 14, 0.25 mg): tolerability-only step